prednisone + ciclosporin + mycophenolate mofetil

This is a combination immunosuppressive regimen consisting of three agents—prednisone, ciclosporin (also known as cyclosporine), and mycophenolate mofetil. This triple therapy is widely used in the management of autoimmune diseases and to prevent organ transplant rejection. - **Prednisone** is a synthetic glucocorticoid corticosteroid that suppresses inflammation and modulates immune responses by binding to the glucocorticoid receptor, affecting gene transcription. - **Ciclosporin** is a calcineurin inhibitor that blocks T-cell activation by inhibiting the phosphatase activity of calcineurin, thereby reducing interleukin-2 production. - **Mycophenolate mofetil** is an antimetabolite immunosuppressant; it acts as a prodrug for mycophenolic acid, which inhibits inosine monophosphate dehydrogenase (IMPDH) in lymphocytes, blocking de novo purine synthesis essential for T and B cell proliferation. The combination provides synergistic immunosuppression through distinct mechanisms targeting multiple steps in immune activation. It has been studied and used primarily for preventing acute rejection after solid organ transplantation (such as kidney transplants) and for treating certain autoimmune conditions like idiopathic membranous nephropathy[3][4][1]. The regimen may be adjusted based on patient tolerance or specific clinical scenarios.

Brand names

CellCeptMyfenaxMyhibbin

Other names

mycophenolic acid morpholinoethyl ester